Previous 10 | Next 10 |
Sarah Silbiger/Getty Images News Sen. Ron Wyden (D-Ore.) has released a document titled "Principles for Drug Reform" that proposes giving Medicare the ability to negotiate prescription drug prices and lowering out-of-pocket costs for consumers at pharmacies. He wants to give the HHS Secr...
Income investors often shy away from high-yielding dividend stocks because of the risk. If a stock is paying 10% or more, it's not likely that the dividend will remain at that yield for too long. But if you are patient, it isn't impossible to earn back that high of a percentage of your orig...
The Fed could begin raising rates sooner than 2023. Healthcare and utilities are climbing our sector ranking. The top stocks in our universe today. For further details see: The Fed Has Spoken: Stocks To Buy Now
Al Drago/Getty Images News The Supreme Court declined to take up an appeal from Abbvie (ABBV) challenging a lower court ruling that said the drugmaker lodged a "sham" patent complaint against Perrigo (PRGO) over AndroGel. The 3rd U.S. Circuit Court of Appeals last year found that Abbvie viola...
I wrote about Kroger last time as a contrarian play with a large upside potential (up to ~50%) in the near to mid-term (3~5 years). This article focuses on its prospects in the longer term, and examines it under the framework of perpetual growth and Buffett’s 10x Pretax Rule. ...
Shanghai's Zai Lab announced a four-drug immuno-oncology deal with MacroGenics worth over $1.4 billion. Beijing's LinkDoc Technology, an AI-driven healthcare company based on cancer patient data, filed to IPO on the NASDAQ exchange. Suzhou Innovent Bio has dosed the first person i...
"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. The 65 Aristocrats screened as of June 17, 2021 represented all eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ran...
In May, we received $581.67 in dividend income! This was a 32.19% year over year increase compared to May 2020. Until the dividend cut is finalized, we are still receiving a boatload of dividend income from AT&T. This year, I have been writing about how our dividend stock purc...
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight. The o...
With Humira's LOE looming in 2023, AbbVie stands to lose billions of dollars in revenues. Estimating Humira's likely losses to biosimilars in the US in 2023 and onward is more art than science, albeit there are plentiful clues to work with. AbbVie's long-term guidance around its U...
News, Short Squeeze, Breakout and More Instantly...
2024-04-29 11:00:06 ET Evan Seigerman from BMO Capital issued a price target of $180.00 for ABBV on 2024-04-29 09:49:00. The adjusted price target was set to $180.00. At the time of the announcement, ABBV was trading at $158.5841. The overall price target consensus is at...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
2024-04-28 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...